MetaHeps

MetaHeps provides solutions for drug-induced liver injury (DILI) in clinical drug-development and postmarketing.

MetaHeps – First technology to diagnose or exclude DILI in individual patients. MetaHeps is an unique service provider that generates a personalized cell model reflecting individual drug hepatotoxicity from a small patient blood sample. Customers are research driven pharmaceutical companies and global acting CROs, using Metaheps’ services in clinical phases of drug development as well as postmarketing to diagnose or exclude Druginduced liver injury (DILI) in individual patients.